Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors Review
| Authors: | Chauhan, A.; Chan, K.; Halfdanarson, T. R.; Bellizzi, A. M.; Rindi, G.; O’Toole, D.; Ge, P. S.; Jain, D.; Dasari, A.; Anaya, D. A.; Bergsland, E.; Mittra, E.; Wei, A. C.; Hope, T. A.; Kendi, A. T.; Thomas, S. M.; Flem, S.; Brierley, J.; Asare, E. A.; Washington, K.; Shi, C. |
| Review Title: | Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors |
| Abstract: | The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP-NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP-NETs from poorly differentiated neuroendocrine carcinoma. In addition, because of major advancements in diagnostic and therapeutic technologies for GEP-NETs, AJCC version 9 advocates against the use of serum chromogranin A for the diagnosis and monitoring of GEP-NETs. Furthermore, AJCC version 9 recognizes the increasing role of endoscopy and endoscopic resection in the diagnosis and management of NETs, particularly in the stomach, duodenum, and colorectum. Finally, T1NXM0 has been added to stage I in these disease sites as well as in the appendix. © 2024 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society. |
| Keywords: | cancer survival; survival analysis; gene mutation; united states; pancreatic neoplasms; cancer staging; cancer diagnosis; neoplasm staging; protein function; colorectal cancer; protein blood level; gene; pathology; diagnostic imaging; protein p53; neuroendocrine tumor; gene identification; diagnosis; pancreas tumor; endoscopic surgery; appendectomy; cancer classification; intestine tumor; intestinal neoplasms; stomach neoplasms; therapy; predictive value; stomach tumor; neuroendocrine tumors; pancreas islet cell tumor; colectomy; chromogranin a; pancreatic neuroendocrine tumor; gastroenteropancreatic neuroendocrine tumor; procedures; tp53 gene; rb1 gene; cancer prognosis; gastroenteropancreatic neuroendocrine tumors; humans; human; article; gastro-enteropancreatic neuroendocrine tumor; gastrointestinal neuroendocrine tumor; american joint committee on cancer (ajcc) version 9; cancer staging protocols; appendiceal neuroendocrine tumor; colorectal neuroendocrine tumor; duodenal neuroendocrine tumor; gastric neuroendocrine tumor; ileal neuroendocrine tumor |
| Journal Title: | CA - A Cancer Journal for Clinicians |
| Volume: | 74 |
| Issue: | 4 |
| ISSN: | 0007-9235 |
| Publisher: | Wiley-Blackwell |
| Date Published: | 2024-07-01 |
| Start Page: | 359 |
| End Page: | 367 |
| Language: | English |
| DOI: | 10.3322/caac.21840 |
| PUBMED: | 38685134 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
